At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 23, 2026 at 16:05 ET
Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expenses, but strengthened its balance sheet with €530.4 million in cash after a $700.3 million public offering. The company remains on track to report topline Phase 3 data for obefazimod in ulcerative colitis in late Q2 2026, and appointed a new Chief Commercial Officer to prepare for potential commercialization.
- Net loss widened to €336.1 million in 2025 from €176.2 million in 2024
- Cash, cash equivalents, and short-term investments totaled €530.4 million as of December 31, 2025
- Raised $700.3 million (€597.2 million) in a public offering in July 2025
- DSMB found no new safety signals in the Phase 3 ABTECT-UC trial; topline results expected late Q2 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access